← Eichor
Condition: Lupus Nephritis Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Lupus Nephritis

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Dose Escalation Study With Bispecific Antibodies in Adult Participants With Lupus Nephritis
Phase 1 · 18 location(s) · Regeneron Pharmaceuticals · NCT06975787US Zamto-cel Autoimmune Diseases
Phase 1 · 1 location(s) · Miltenyi Biomedicine GmbH · NCT06708845A Safety and Efficacy Study Evaluating CTX112 in Adult Subjects With Refractory Autoimmune Disease
Phase 1 · 14 location(s) · CRISPR Therapeutics · NCT06925542Lupus Landmark Study: A Prospective Registry and Biorepository
Phase N/A · 25 location(s) · Lupus Research Alliance · NCT05934149RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic
Phase 1/Phase 2 · 23 location(s) · Cabaletta Bio · NCT06121297A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Pati
Phase 2 · 101 location(s) · Novartis Pharmaceuticals · NCT06581198A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite I
Phase 2 · 96 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07015983Disease Activity Biomarkers in Patients With Systemic Lupus Erythematosus
Phase N/A · 1 location(s) · Cliniques universitaires Saint-Luc- Université Catholique de · NCT05443516PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis
Phase 4 · 15 location(s) · Aurinia Pharmaceuticals Inc. · NCT07611214Minimizing Glucocorticoid Administration in Patients With Proliferative Lupus Nephritis
Phase 4 · 1 location(s) · Institutul Clinic Fundeni · NCT05207358Biomarker Development for Autoimmune Disorders Involving the Kidneys
Phase N/A · 1 location(s) · Oslo University Hospital · NCT07666711A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Phase 1/Phase 2 · 19 location(s) · Nkarta, Inc. · NCT06557265A Clinical Study of YTS109 Cell for R/R Autoimmune Diseases
Phase 1 · 1 location(s) · China Immunotech (Beijing) Biotechnology Co., Ltd. · NCT07104721Treatment of Lupus Nephritis With Allogeneic Mesenchymal Stem Cells
Phase 2 · 1 location(s) · Red de Terapia Celular · NCT03673748Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)
Phase 2 · 12 location(s) · Autolus Limited · NCT07053800Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.
Phase 1/Phase 2 · 1 location(s) · Beijing GoBroad Hospital · NCT06947473Gonadotropin-releasing Hormone Agonist (GnRHa) in Ovarian Preservation in SLE Subjects Receiving Cyclophosphamide as Det
Phase N/A · 1 location(s) · National Institute of Arthritis and Musculoskeletal and Skin · NCT05567198CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Phase 1 · 1 location(s) · The Children's Hospital of Zhejiang University School of Med · NCT07305116A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Disease
Phase 1 · 28 location(s) · Juno Therapeutics, Inc., a Bristol-Myers Squibb Company · NCT07115745A Study to Evaluate the Efficacy, Safety, and Tolerability of Human Sialidase Fusion Protein (HLX79) in Combination With
Phase 2 · 17 location(s) · Shanghai Henlius Biotech · NCT07038382A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With
Phase 1 · 14 location(s) · Allogene Therapeutics · NCT07085104The Pediatric Lupus Nephritis Mycophenolate Mofetil (PLUMM) Study
Phase 2 · 19 location(s) · Children's Hospital Medical Center, Cincinnati · NCT05538208Safety and Efficacy of PRG-2311 for Refractory Lupus Nephritis and IgG4-Related Disease
EARLY_Phase 1 · 1 location(s) · Tongji Hospital · NCT06497361RY_SW01 Cell Injection Therapy in Active Lupus Nephritis
Phase 2 · 1 location(s) · Jiangsu Renocell Biotech Company · NCT06058078NK010 or NK042 in Combination With Rituximab for Refractory Systemic Lupus Erythematosus/Lupus Nephritis
Phase 1 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06676631Wellness & Workforce Solution for Lupus/Lupus Nephritis
NA · 1 location(s) · Morehouse School of Medicine · NCT06217107High Quality Evidence of Chinese Lupus Nephritis (HELP)
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT03001973UB-VV410 in Subjects With Active Refractory Systemic Lupus Erythematosus or Lupus Nephritis
Phase 1 · 1 location(s) · Nanjing IASO Biotechnology Co., Ltd. · NCT07109986A Study of LCAR-AIO in Subjects With Relapsed/Refractory Systemic Lupus Erythematosus
EARLY_Phase 1 · 1 location(s) · Union Hospital, Tongji Medical College, Huazhong University · NCT06653556The Effect of Mycophenolate Mofetil and Cyclophosphamide on the Lymphocyte Subsets in Patients With Proliferative Lupus
NA · 1 location(s) · The University of Hong Kong · NCT02954939
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.